I have sat with patients who told me they had tried everything. Six months of antibiotics. Topical retinoids they stopped because their skin peeled. A benzoyl peroxide wash that dried them out so badly they gave up within two weeks. By the time they arrived in aesthetic practice, they had decided their acne was simply who they were.
It was not. The problem was not their acne. The problem was a treatment plan that was never actually a plan.
What a structured acne assessment covers
Before any treatment decision, the clinical picture needs to be clear. The type of acne, the severity grade, the treatment history, and any prescribing history all shape what comes next.
NICE NG198 distinguishes between comedonal, papulopustular, and nodulocystic presentations, and grades severity as mild, moderate, or severe. These categories matter because they direct the treatment pathway. A mild comedonal presentation without significant inflammation is a different clinical challenge from moderate papulopustular acne with post-inflammatory marks. Treating them identically is not a plan.
Treatment history is the section most aesthetic practitioners underweight. Has this person had topical antibiotics, and for how long? Have they ever completed a retinoid course? Was benzoyl peroxide part of their previous regimen, or was it missing? Antibiotic resistance is now clinically significant in acne management in the UK, and a patient who has had three or more courses of topical antibiotics without improvement should not be started on another round.
Scarring risk belongs in the initial consultation. Patients with darker skin tones are at higher risk of post-inflammatory hyperpigmentation and certain scar types. That risk informs how aggressively to treat and how quickly to escalate.
The NICE NG198 treatment ladder
NG198 sets out a structured approach. It is worth knowing because it defines the standard of care, and aesthetic practitioners working in acne need to be operating within it, not parallel to it.
For mild to moderate acne, topical combination therapy is first line. The evidence supports a fixed-dose combination of an antibiotic (usually clindamycin) with benzoyl peroxide, or a topical retinoid with benzoyl peroxide. Benzoyl peroxide is non-negotiable in any plan containing an antibiotic because it prevents resistance development.
Antibiotic monotherapy is not recommended. This is not a subtle point. The guideline is explicit that topical or oral antibiotics should always be combined with benzoyl peroxide or a topical retinoid. Single-antibiotic regimens have been associated with increasing C. acnes resistance in UK and European populations.
For moderate to severe acne, oral antibiotics (lymecycline or doxycycline are preferred) combined with a topical retinoid and benzoyl peroxide form the standard oral pathway. Duration matters. Oral antibiotics for acne should be reviewed at 12 weeks. If there is no improvement at that point, continuing is not appropriate.
Isotretinoin sits at the top of the ladder and remains a prescription-only medicine requiring initiation by a dermatologist with access to the relevant monitoring pathway. Aesthetic practitioners who reach isotretinoin candidates should have a clear, documented referral route.
What aesthetic practitioners add to this framework
The NICE pathway is designed for primary care. Aesthetic practice brings additional clinical tools.
Chemical exfoliation with salicylic acid, glycolic acid, or azelaic acid addresses the comedone burden and the acid mantle disruption that worsens inflammatory acne. These are not replacements for medical management in moderate or severe presentations. They are adjuncts that address the surface environment and support treatment adherence between professional appointments.
Light-based treatments, including blue light and intense pulsed light, have evidence in mild to moderate acne, primarily through targeted reduction of C. acnes populations and sebaceous activity. They are additional tools, not alternatives to topical or systemic medical management in moderate presentations.
The realistic scope for non-prescribing aesthetic practitioners in acne management: comedonal and mild inflammatory presentations, adjunctive treatment alongside GP-initiated medical therapy, and clear referral when medical management is needed and outside your prescribing scope.
The documentation question
Any treatment plan for acne in aesthetic practice requires documentation. What you assessed, what you prescribed or recommended, what you deferred, and to whom you referred. The JCCP expects practitioners to demonstrate that their practice sits within their training and competence. Acne is a medical condition. Managing it in aesthetic practice without a clear clinical framework, documented evidence of training, and a referral pathway is an audit risk.
That applies equally when you are working alongside a prescriber as when you are working alone. The plan is yours. The documentation is yours.
If you want a structured clinical framework for acne management in aesthetic practice, built around current NICE guidance and the evidence on antibiotic resistance, microbiome disruption, and treatment sequencing, Acne Decoded covers the full consultation model, treatment ladder, and prescribing considerations for UK practitioners. The course is £150 and available now.